DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award

DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award is sponsored by Defense Health Agency Contracting Activity - DHACA. Supports new, innovative, high-risk, high-gain ideas aimed at ALS drug or therapy discovery, focusing on hypothesis-driven studies generating preliminary data for future therapeutic investigations.

A **. gov** website belongs to an official government organization in the United States.

* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.

gov Maintenance Calendar DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award Defense Health Agency Contracting Activity - DHACA Document Type:Grants Notice Funding Opportunity Number:HT942524ALSRPTIA Funding Opportunity Title:DOD Amyotrophic Lateral Sclerosis, Therapeutic Idea Award Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Science and Technology and other Research and Development Expected Number of Awards:10 Assistance Listings:12.

420 -- Military Medical Research and Development Cost Sharing or Matching Requirement:No Last Updated Date:Apr 23, 2024 Original Closing Date for Applications:Jul 10, 2024 Current Closing Date for Applications:Jul 10, 2024 Archive Date:Aug 09, 2024 Estimated Total Program Funding:$ 9,800,000 Eligible Applicants:Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Additional Information on Eligibility: ## Additional Information Agency Name:Defense Health Agency Contracting Activity - DHACA Description:The FY24 ALSRP Therapeutic Idea Award (TIA) supports new, innovative, high-risk, high-gain ideas aimed at Amyotrophic Lateral Sclerosis (ALS) drug or therapy discovery.

The studies supported by this award mechanism are expected to be hypothesis-driven and generate preliminary data for future avenues of therapeutic investigation. **Projects that focus primarily on pathophysiology of ALS without development of a therapy are outside the scope of this funding opportunity.

** Applications may demonstrate the ability to achieve interpretable results in the absence of preliminary data supporting the hypothesis. While the inclusion of preliminary data is not prohibited, **the strength of the application should rely on the approach.

** **The key elements of this award mechanism are:** * **Innovation:** Research deemed innovative may introduce a new paradigm, challenge current paradigms, introduce novel concepts or technologies, or exhibit other uniquely creative qualities that may lead to potential therapeutics for ALS. * **Impact:** The FY24 TIA can be for a specific ALS subtype and does not have to broadly apply to all patients.

Research **should be non-incremental** and pioneer transformative results that could lay the foundation for a new direction in the field of ALS therapy development. Incremental research does not meet the intent of this funding opportunity.

* **Strong Scientific Rationale:** Projects that address in the intent of the mechanism should include a well-formulated, testable hypothesis based on strong scientific rationale that holds translational potential to improve ALS treatment and/or advance a novel treatment modality.

* **Biomarkers:**Applicants are required to include consideration to biomarker(s) development in parallel with their proposed Therapeutic Idea Award research for eventual clinical trials.

Efforts should be mechanism-specific and may include development of target engagement biomarkers, objective pharmacodynamic biomarkers to measure the biological effect of an investigational therapeutic, or predictive/cohort-selective biomarkers that indicate whether a specific therapy will be effective in an individual patient or patient subgroup, including pre-symptomatic gene carriers.

Development of markers for the purposes of diagnosis, prognosis, or measurement of disease progression apart from consideration of the therapeutic development process will not be supported and instead investigators should consider the Clinical Outcomes and Biomarkers Award (HT942524ALSRPCOBA). Link to Additional Information:[](https://www. grants.

gov/search-results-detail/353167) Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: #### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.

Unsaved changes will be lost.